作者: Masanori Onda , Satoru Matsuda , Shozo Higaki , Takuo Iijima , Jun-ichi Fukushima
DOI: 10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5
关键词: Pathology 、 Gene expression 、 Cancer research 、 Osteosarcoma 、 Survival analysis 、 Medicine 、 ErbB 、 Conventional Osteosarcoma 、 Immunohistochemistry 、 Cancer 、 Survival rate
摘要: BACKGROUND It has been reported that the c-erbB-2 protooncogene is frequently amplified and overexpressed in many types of cancers, except sarcomas hematological malignancies. METHODS Expression ErbB-2 tumors 26 patients with conventional osteosarcoma was evaluated by immunoblotting. DNA from tissues expressed were analyzed Southern blot hybridization to examine gross rearrangement gene. The also surveyed for presence genetic mutation transmembrane domain polymerase chain reaction–single-stranded conformation polymorphism analysis. In addition, possible correlation expression gender, age, histopathologic subtype, response chemotherapy analyzed. Survival analysis performed Kaplan-Meier test using approximate chi-square statistic log-rank test. RESULTS The protein detected 11 (42%) immunoblot Expression confirmed immunohistochemical studies specific anti-ErbB-2 monoclonal antibody. However, neither amplification gene nor evidence significant found these osteosarcomas. examined immunoblotting most strongly correlated early pulmonary metastases (P < 0.05). Among entire group this study, life table survival apparent significantly worse than little 0.01). CONCLUSIONS In 42% osteosarcomas, tumor cells ErbB-2. metastasis poor rate patient. These data suggest plays a role aggressive growth promotion metastatic potential would be useful prognostic marker patients. Cancer 1996;77:71-8.